Life Sciences and Health Care Horizon Guide
Dive into Horizons — your go-to place for insights, events, and perspectives from our global Life Sciences and Health Care team. Stay ahead with the latest trends, challenges, and breakthroughs shaping the industry.
Our Horizons edition brings together insights from across our global Life Sciences and Health Care team to explore the issues and developments shaping the future of the industry. With contributions from lawyers spanning the U.S., Europe, Asia-Pacific, Latin America, and the Middle East, the publication offers practical, forward-looking perspectives on topics impacting companies worldwide.
Our cross-practice approach provides a broad view of emerging trends, whether regulatory, transactional, geopolitical or technological, through the lends of what they mean for businesses operating in this space.
Life Sciences and Health Care Horizons Edition is our firm’s annual publication designed to help clients stay ahead in a constantly evolving sector. We hope you find this year’s insights timely, relevant and thought-provoking.
Introducing the 2025 Horizons edition:
Contacts
Horizons at a glance
In our latest Horizons edition, we highlight standout chapters that offer a glimpse into the key insights and forward-looking perspectives shaping what’s next across the global sector landscape.
United States
What trends will shape U.S. life sciences and health care in 2025?
Explore what’s ahead:
- Post-election regulatory outlook
- Real-world data in focus
- FDA: What’s next?
- Pharmacy access under scrutiny
- Drug Supply Chain Security Act: What it means now
Europe
This essential chapter unpacks critical developments shaping the industry, including:
- EU health technology and regulatory reform
- Pharma data exclusivity
- Regulation of health influencers in France
- New EU regulations on blood, tissues, and cells
APAC
In the APAC chapter of our 2025 Horizons edition, we highlight “China issues new rules on domestic responsible persons”, which covers the NMPA’s Interim Provisions issued on 13 November 2024 and set to take effect on 1 July 2025. These new rules strengthen regulatory oversight of overseas marketing authorization holders and their appointed domestic responsible persons, who will now share joint responsibility for fulfilling drug marketing authorization obligations and take on a much more prominent, consumer-facing role.
Cross-jurisdictional
The cross-jurisdictional chapter features the complex regulatory landscape governing clinical trials involving genetically modified organisms (GMOs) in the EU. The piece explores how countries such as Belgium, Germany, Italy, the Netherlands, Spain, and France navigate a patchwork of evolving rules shaped by safety and environmental concerns.
AI and Digital Health
What’s next for AI and Digital Health in life sciences and health care?
Discover the latest insights driving the future of AI and Digital Health in our 2025 Horizons edition.
Get a glimpse of what’s next:
- AI in health care: What’s next?
- Navigating digital health and SaMD regulation
- Changes to reimbursement framework
- Compliance
Horizons events
Each year, we host Horizons events across the globe to spotlight key articles from our latest edition and explore the trends shaping the future of the life sciences and health care industry. These events bring together industry leaders to share their perspectives on the most pressing issues impacting the global landscape.
Below, you’ll find more information on this year’s upcoming events – including event details, agendas, and featured speakers.
25 September 2025
25 September 2025
22 October 2025
22 October 2025
Featured insights
View more insights and analysis
